Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Clinical trial results for Calistoga Pharmaceuticals’ CAL-101

Calistoga Pharmaceuticals, Inc., announced interim results from the ongoing Phase 1 trial evaluating CAL-101, a PI3K inhibitor, showing promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At this interim assessment, 29 percent of CLL patients treated in the cohort expansion dose levels had partial responses observed after 28 days of therapy (1 cycle) and 94 percent have achieved evidence of biologic activity with a greater than 50 percent decrease in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Endocyte announces close of $26 million equity financing

Endocyte, Inc., completed a $26 million extension of its Series C financing. This round included participation from all existing institutional investors including Sanderling Ventures, Burrill & Company, American Bailey Ventures, Blue Chip Venture Company, and Triathlon Medical Ventures. Clarian Health Ventures also participated as a new investor.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Targacept reports positive Phase 2b trial results for depression treatment

Targacept, Inc. (NASDAQ: TRGT) presented data from its Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.  In the trial, the add-on TC-5214 arm (TC-5214 + citalopram) outperformed the add-on placebo arm (placebo + citalopram) on the primary outcome measure, the Hamilton Rating Scale for Depression-17, or HAM-D, and all of the secondary Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Q&A with ExonHit Therapeutics’ Loïc Maurel, MD

We recently spoke with Loïc Maurel, M.D., president of ExonHit Therapeutics’ Management Board, one of the companies presenting at the Eighth Annual BIO Investor Forum: Can you describe the top priorities or upcoming milestones for your company? This year will be the first year of product commercialization for ExonHit with the launch of EHT Dx21, a blood-based diagnostic test for Alzheimer’s disease. The Company is also focused on the outlicensing of EHT 0202, ExonHit’s lead Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Methylgene to receive equity investment from Otsuka Pharmaceutical

MethylGene Inc. (TSX: MYG) agreed to issue 3,686,182 common shares to Otsuka Pharmaceutical Co., Ltd. as part of a research collaboration and license agreement for the development of  small molecule kinase inhibitors for ocular diseases excluding cancer. Otsuka will acquire newly issued common shares of MethylGene at a purchase price of approximately $0.43 per share for gross proceeds of $1,500,000. In September 2009, MethylGene announced that Otsuka had extended the research portion of the collaboration Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,